Johnson Johnson

CONSUMER HEALTH SEGMENT (2)

SKIN HEALTH / BEAUTY

WOMEN'S HEALTH

WOUND CARE / OTHER

OTC US Intl WW

US
Intl
WW

ORAL CARE
US
Intl
WW

BABY CARE
US
Intl
WW

WW

WW

US Intl WW

US Intl WW

US Intl WW REPORTED SALES vs. PRIOR PERIOD (\$MM)

			THIRD QUARTE	:R	
				% Change	
2	2021	2020	Reported	Operational (1)	Currency
_					
\$	686	601	14.0%	14.0%	-
	686	541	26.9%	22.8%	4.1%
	1,372	1,142	20.1%	18.2%	1.9%
	•	,			
	500	F70	0.50/	0.50/	
	569 555	572 577	-0.5% -3.8%	-0.5% -5.5%	- 1.7%
	1,124	1,149	-2.2%	-3.0%	0.8%
	150	164	-8.4%	-8.4%	-
	248	248	0.1%	-1.8%	1.9%
	398	412	-3.3%	-4.5%	1.2%
	95	91	5.2%	5.2%	
	296	302	-2.0%	-3.1%	1.1%
	391	393	-0.3%	-1.2%	0.9%
	331	333	-0.576	-1.270	0.576
	3	3	20.1%	20.1%	-
	229	227	0.5%	0.6%	-0.1%
	232	230	0.8%	0.8%	0.0%
	122	125	-2.6%	-2.6%	_
	61	64	-5.2%	-9.0%	3.8%
-	182	189	-3.5%	-4.8%	1.3%
	.02	100	0.070	4.070	1.070
	1,625	1,556	4.5%	4.5%	-
	2,075	1,958	5.9%	3.7%	2.2%
\$	3,700	3,514	5.3%	4.1%	1.2%

See footnotes at end of schedule

TOTAL CONSUMER HEALTH

REPORTED	SALES	vs. PR	IOR P	<u>ERIOD (</u>	\$MM	١

NINE MONTHS								
		-		% Change				
	2021	2020	Reported	Operational (1)	Currency			
	<u></u>				<u></u>			
\$	1,960	1,917	2.2%	2.2%	-			
	1,894	1,722	10.0%	3.9%	6.1%			
	3,854	3,639	5.9%	3.0%	2.9%			
	1,862	1,767	5.4%	5.4%	_			
	1,595	1,506	5.9%	2.1%	3.8%			
	3,457	3,273	5.6%	3.9%	1.7%			
	478	510	-6.2%	-6.2%				
	762	694	9.9%	5.9%	4.0%			
_	1,240	1,204	3.0%	0.8%	2.2%			
	1,240	1,204	3.076	0.076	2.270			
	288	279	3.3%	3.3%	-			
	879	831	5.8%	4.6%	1.2%			
	1,167	1,110	5.2%	4.3%	0.9%			
	9	10	-5.7%	-5.7%	-			
	675	654	3.1%	2.3%	0.8%			
	684	664	3.0%	2.1%	0.9%			
	390	370	5.3%	5.3%	_			
	186	175	5.8%	0.0%	5.8%			
	575	545	5.4%	3.6%	1.8%			
	0.0	0.0	0.170	0.070				
	4,987	4,853	2.8%	2.8%				
	4,96 <i>1</i> 5,991	4,653 5,582	7.3%	3.5%	3.8%			
\$	10,978	10,435	5.2%	3.1%	2.1%			
<u> </u>	10,310	10,433	J. Z /0	3.170	2.1/0			

Name			REPOR	RTED SALES vs. PR THIRD QUARTE	RIOR PERIOD (\$MM)		
STEPHY STATE STA				mms goaltre			
S	PHARMACEUTICAL SEGMENT (2,3)	<u>2021</u>	2020	Reported	Operational (1)	Currency	<u>2021</u>
S	IMMUNOLOGY						
Int		\$ 2,771	2,558	8.3%	8.3%	-	\$ 7
New						1.5%	4
US 480 634 -24,3% -24,3% -24,3% -1 US Exports (10) 47 78 -40,2% -1 US Exports (11) 234 209 12,2% -17,4% -18,3% 0,9% SIMPONI SIMPONI ARIA US 295 312 -5,3% -5,3% -5,3% -0,4% UW 571 592 -3,3% -3,1% -0,2% STELARA US 1,569 1,313 19,5% 19,5% -1 Intl 809 634 27,7% 26,3% 1,4% WW 2,378 1,947 22,2% 21,7% 0,5% TREMFYA US 376 222 69,7% 69,7% -0,5% Intl 161 105 52,5% 50,5% 2,0% WW 537 327 64,1% 63,5% 0,6% OTHER INMUNOLOGY US 3 -	WW			12.2%			12
US	REMICADE						
Intil		480	634	-24.3%	-24.3%	-	1
SIMPONI / SIMPONI ARIA 18.3% 0.9%	US Exports (4)	47	78	-40.2%	-40.2%	-	
SIMPONI / SIMPONI ARIA US 295 312 -5.3% -5.3% - 0.45% WW 571 592 -3.3% -3.1% -0.2% STELARA US 1,569 1,313 19.5% 19.5% - 0.4% WW 2,378 1,947 22.2% 21.7% 26.3% 1.4% WW 2,378 1,947 22.2% 21.7% 26.3% 1.4% WW 2,378 1,947 22.2% 21.7% 0.5% TREMFYA US 376 222 69.7% 69.7% - 0.5% MW 537 327 64.1% 63.5% 0.6% 0.6% OTHER IMMUNOLOGY US 3 -	Intl	234	209	12.2%	8.1%	4.1%	
US	WW	761	921	-17.4%	-18.3%	0.9%	2
Intt	SIMPONI / SIMPONI ARIA						
STELARA US	US	295	312	-5.3%	-5.3%	-	
STELARA US	Intl	276	280	-1.1%	-0.7%	-0.4%	
1,569	WW	571	592	-3.3%	-3.1%	-0.2%	1
New 1,389 634 27.7% 26.3% 1.4% 2.378 1.947 22.2% 21.7% 0.5% 1.84% 1.	STELARA						
Name	US	1,569	1,313	19.5%	19.5%	-	4
TREMFYA US 376 222 69.7% 6	Intl	809	634	27.7%	26.3%	1.4%	2
US 161 105 52.5% 50.5% 2.0%	WW	2,378	1,947	22.2%	21.7%	0.5%	6
Inti	<u>TREMFYA</u>						
STATE STAT	US	376	222	69.7%	69.7%	-	
OTHER IMMUNOLOGY US	Intl	161	105	52.5%	50.5%	2.0%	
US 101	WW	537	327	64.1%	63.5%	0.6%	1
Inti	OTHER IMMUNOLOGY						
NFECTIOUS DISEASES US	US	3	-				
NFECTIOUS DISEASES US	Intl	0	3	*	*	*	
S	WW	3	3	-26.4%	-27.5%	1.1%	
Intl	INFECTIOUS DISEASES						
Name						-	1
COVID-19 VACCINE US					55.6%	1.6%	1
US 170 -		1,389	864	60.6%	59.8%	0.8%	3
Intl	·	070					
WW 502 - * * - EDURANT / rilpivirine US 12 11 8.4% 8.4% - Intl 247 226 9.7% 8.7% 1.0% WW 259 236 9.6% 8.6% 1.0% PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA 380 379 0.4% 0.4% - Intl 137 147 -7.1% -8.8% 1.7% WW 517 526 -1.7% -2.2% 0.5% OTHER INFECTIOUS DISEASES US 18 24 -26.0% -26.0% - Intl 93 78 18.3% 15.2% 3.1%			-	*	*	-	
Section Precision Precis					*	-	-
12		502	-	_	•	-	
Intl							
WW 259 236 9.6% 8.6% 1.0% PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA US 380 379 0.4% 0.4% - Intl 137 147 -7.1% -8.8% 1.7% WW 517 526 -1.7% -2.2% 0.5% OTHER INFECTIOUS DISEASES US 18 24 -26.0% -26.0% - Intl 93 78 18.3% 15.2% 3.1%							
PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA US 380 379 0.4% 0.4% -							
S 380 379 0.4% 0.4% -	WW	259	236	9.6%	8.6%	1.0%	
Intl							
WW 517 526 -1.7% -2.2% 0.5% OTHER INFECTIOUS DISEASES US 18 24 -26.0% -26.0% - Intl 93 78 18.3% 15.2% 3.1%							1
OTHER INFECTIOUS DISEASES 18 24 -26.0% -26.0% - Intl 93 78 18.3% 15.2% 3.1%							
US 18 24 -26.0% -26.0% - Intl 93 78 18.3% 15.2% 3.1%		517	526	-1.7%	-2.2%	0.5%	1
Intl 93 78 18.3% 15.2% 3.1%							
WW 110 102 7.8% 5.4% 2.4%	WW	110	102	7.8%	5.4%	2.4%	

REPORTED	CALECUA	DDIAD	DEDIAD	/CRARAL
REPORTED	SALES VS.	PRICK	PERIOD	(SIVIN)

		N	IINE MONTHS		
				% Change	
	2021	2020	Reported	Operational (1)	Currency
					<u></u>
\$	7,932	7,330	8.2%	8.2%	_
•	4,464	3,619	23.3%	17.6%	5.7%
_	12,395	10,950	13.2%	11.3%	1.9%
	,	,,,,,,,			
	1,508	1,852	-18.6%	-18.6%	_
	197 721	321 673	-38.7% 7.1%	-38.7% 1.4%	- 5.7%
_	2,426	2,846	-14.8%	-16.1%	1.3%
	2,420	2,040	-14.0%	-10.176	1.3%
	840	840	0.0%	0.0%	-
	877	827	6.1%	2.8%	3.3%
	1,717	1,667	3.0%	1.4%	1.6%
	4,396	3,668	19.9%	19.9%	-
	2,404	1,795	33.9%	27.5%	6.4%
	6,800	5,463	24.5%	22.4%	2.1%
	975	650	50.1%	50.1%	_
	459	316	45.4%	38.0%	7.4%
	1,434	965	48.5%	46.1%	2.4%
	1,101				,
	15	-	*	*	_
	3	9	-68.6%	-70.8%	- 2.2%
_	18	9	91.6%	89.5%	2.2%
	10	9	91.0%	09.576	2.170
	1,635	1,265	29.2%	29.2%	-
	1,788	1,397	28.0%	23.2%	4.8%
	3,424	2,662	28.6%	26.1%	2.5%
	404				
	421 346	-	*	*	-
_	766		*	*	_
	700	-			-
	31	33	-4.8%	-4.8%	-
	733	684	7.2%	1.7%	5.5%
	764	716	6.7%	1.4%	5.3%
	1,128	1,154	-2.2%	-2.2%	-
	440	461	-4.6%	-8.6%	4.0%
	1,568	1,615	-2.9%	-4.1%	1.2%
	55	79	-29.6%	-29.6%	-
	270	252	6.9%	2.6%	4.3%
	325	331	-1.8%	-5.0%	3.2%

REPORTED SALES vs. PRIOR PERIOD (\$MM)
THIRD QUARTER

Table Tabl	- 1.3% 0.7% - 1.7% 1.2% - 1.1% 0.4%
NEUROSCIENCE 10.2	- 1.3% 0.7% - 1.7% 1.2% - 1.1% 0.4%
NEUROSCIENCE US	- 1.3% 0.7% - 1.7% 1.2% - 1.1% 0.4%
US 10.2% 10.2% 10.2% 10.2% 10.2% 10.1% 10.1% 10.2%	1.3% 0.7% - 1.7% 1.2% - 1.1% 0.4%
Intil 854 846 0.8% -0.5%	1.3% 0.7% - 1.7% 1.2% - 1.1% 0.4%
Table Tabl	0.7% - 1.7% 1.2% - 1.1% 0.4%
CONCERTA / Methylphenidate US 35	- 1.7% 1.2% - 1.1% 0.4%
US 157 149 14.2% 12.5% 12.5% 12.5% 12.5% 12.5% 12.5% 12.5% 14.2% 12.5% 14.2% 12.5% 14.2% 12.5% 14.2% 13.3% 14.2% 13.3% 14.2% 13.3% 14.2% 13.3% 14.5% 3.3% 14.5% 3.3% 14.5% 3.3% 14.5% 3.3% 14.5% 3.3% 14.5% 3.2% 14.5% 3.2% 14.3% 3.2% 14.3% 3.2% 14.3% 3.2% 14.3% 3.2% 14.3% 3.2% 14.3% 3.2% 14.3% 3.2% 14.3% 3.2% 14.3% 3.2% 14.3% 14.3% 3.2% 14.3% 14.3% 3.2% 14.3% 14.3% 3.2% 14.3% 14.3% 3.2% 14.3% 14.3% 3.2% 14.3% 14.3% 14.3% 14.3% 3.2% 14.3% 1	1.7% 1.2% - 1.1% 0.4%
Inti	1.7% 1.2% - 1.1% 0.4%
Inti	1.2% - 1.1% 0.4%
NV	1.2% - 1.1% 0.4%
INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA	- 1.1% 0.4% -
INVEGA TRINZA / TREVICTA US	1.1% 0.4% -
US 648 585 11.0% 11.0% Intl 355 341 4.3% 3.2% WW 1,004 926 8.5% 8.1% RISPERDAL CONSTA VS 71 70 1.3% 1.3% Intl 69 81 -16.7% -16.0% - WW 140 152 -8.4% -8.0% - OTHER NEUROSCIENCE US 81 60 34.7% 34.7% Intl 307 317 -2.9% -4.8% WW 388 377 3.1% 1.5% ONCOLOGY US 1,525 1,267 20.3% 20.3% Intl 2,140 1,862 14.9% 13.8% WW 3,665 3,129 17.1% 16.5% DARZALEX US 841 585 43.7% 43.7%	1.1% 0.4% -
Intl	1.1% 0.4% -
No.	0.4%
RISPERDAL CONSTA US	-
US	
US	
Intl 69	0.7%
WW 140 152 -8.4% -8.0% OTHER NEUROSCIENCE US 81 60 34.7% 34.7% Intl 307 317 -2.9% -4.8% WW 388 377 3.1% 1.5% ONCOLOGY US 1,525 1,267 20.3% 20.3% Intl 2,140 1,862 14.9% 13.8% WW 3,665 3,129 17.1% 16.5% DARZALEX US 841 585 43.7% 43.7%	
OTHER NEUROSCIENCE US 81 60 34.7% 34.7% Intl 307 317 -2.9% -4.8% WW 388 377 3.1% 1.5% ONCOLOGY US 1,525 1,267 20.3% 20.3% Intl 2,140 1,862 14.9% 13.8% WW 3,665 3,129 17.1% 16.5% DARZALEX US 841 585 43.7% 43.7%	
US Intl 81 60 34.7% 34.7% WW 307 317 -2.9% -4.8% WW 388 377 3.1% 1.5% ONCOLOGY US 1,525 1,267 20.3% 20.3% Intl 2,140 1,862 14.9% 13.8% WW 3,665 3,129 17.1% 16.5% DARZALEX US 841 585 43.7% 43.7%	0.4%
Intl 307 317 -2.9% -4.8% WW 388 377 3.1% 1.5% ONCOLOGY 5 1,525 1,267 20.3% 20.3% Intl 2,140 1,862 14.9% 13.8% WW 3,665 3,129 17.1% 16.5% DARZALEX US 841 585 43.7% 43.7%	
WW 388 377 3.1% 1.5% ONCOLOGY 1,525 1,267 20.3% 20.3% Intl 2,140 1,862 14.9% 13.8% WW 3,665 3,129 17.1% 16.5% DARZALEX US 841 585 43.7% 43.7%	-
ONCOLOGY US 1,525 1,267 20.3% 20.3% Intl 2,140 1,862 14.9% 13.8% WW 3,665 3,129 17.1% 16.5% DARZALEX US 841 585 43.7% 43.7%	1.9%
US 1,525 1,267 20.3% 20.3% Intl 2,140 1,862 14.9% 13.8% WW 3,665 3,129 17.1% 16.5% DARZALEX US 841 585 43.7% 43.7%	1.6%
Intl 2,140 1,862 14.9% 13.8% WW 3,665 3,129 17.1% 16.5% DARZALEX US 841 585 43.7% 43.7%	
WW 3,665 3,129 17.1% 16.5% DARZALEX US 841 585 43.7% 43.7%	-
DARZALEX US 841 585 43.7% 43.7%	1.1%
DARZALEX US 841 585 43.7% 43.7%	0.6%
US 841 585 43.7% 43.7%	0.070
	_
	1.7%
	0.8%
<u>ERLEADA</u>	
US 214 152 40.5% 40.5%	-
Intl130 * * *	*
WW 344 206 66.7% 65.8%	0.9%
IMBRUVICA	
US 413 450 -8.3% -8.3%	_
	1.7%
	1.0%
,	1.0%
ZYTIGA / abiraterone acetate	
US 25 58 -57.0% -57.0%	-
	0.3%
WW 548 590 -7.2% -7.5%	0.3%
OTHER ONCOLOGY	
US 32 21 49.6% 49.6%	
	-
	- 0.8%
250 01.070 00.070	

2021 2020 Reported Operational (*) Currency 2,448 2,285 7.2% 7.2% - 2,770 2,565 8.0% 4.1% 3.9% 5,218 4,850 7.6% 5.5% 2.1% 117 150 -22.1% -22.1% - 372 319 16.4% 11.6% 4.8% 489 469 4.1% 0.8% 3.3% 1,882 1,704 10.4% 10.4% - 1,111 983 13.0% 7.6% 5.4% 2,994 2,688 11.4% 9.4% 2.0% 210 220 -4.7% -4.7% - 242 254 -5.1% -8.3% 3.2% 452 475 -4.9% -6.6% 1.7% 239 210 13.9% 13.9% - 1,045 1,008 3.7% 1.5% 2.2% 1,284 1,218 5.5%			NINE MONTHS		
2,448 2,285 7.2% 7.2% - 2,770 2,565 8.0% 4.1% 3.9% 5,218 4,850 7.6% 5.5% 2.1% 117 150 -22.1% -22.1% - 372 319 16.4% 11.6% 4.8% 489 469 4.1% 0.8% 3.3% 1,882 1,704 10.4% 10.4% - 1,111 983 13.0% 7.6% 5.4% 2,994 2,688 11.4% 9.4% 2.0% 210 220 -4.7% -4.7% - - 2,994 2,688 11.4% 9.4% 2.0% 210 220 -4.7% -4.7% - - 2,994 2,688 11.4% 9.4% 2.0% 452 475 -4.9% -6.6% 1.7% 239 210 13.9% 1.5% 2.2% 1,045 1,008				% Change	
2,770 2,565 8.0% 4.1% 3.9% 5,218 4,850 7.6% 5.5% 2.1% 117 150 -22.1% -22.1% - 372 319 16.4% 11.6% 4.8% 489 469 4.1% 0.8% 3.3% 1,882 1,704 10.4% 10.4% - 1,111 983 13.0% 7.6% 5.4% 2,994 2,688 11.4% 9.4% 2.0% 210 220 -4.7% -4.7% - 242 254 -5.1% -8.3% 3.2% 452 475 -4.9% -6.6% 1.7% 239 210 13.9% 13.9% - 1,045 1,008 3.7% 1.5% 2.2% 1,284 1,218 5.5% 3.6% 1.9% 4,364 3,623 20.4% 20.4% - 6,406 5,310 20.6% 15.3%	<u>2021</u>	2020	Reported	Operational (1)	Currency
2,770 2,565 8.0% 4.1% 3.9% 5,218 4,850 7.6% 5.5% 2.1% 117 150 -22.1% -22.1% - 372 319 16.4% 11.6% 4.8% 489 469 4.1% 0.8% 3.3% 1,882 1,704 10.4% 10.4% - 1,111 983 13.0% 7.6% 5.4% 2,994 2,688 11.4% 9.4% 2.0% 210 220 -4.7% -4.7% - 242 254 -5.1% -8.3% 3.2% 452 475 -4.9% -6.6% 1.7% 239 210 13.9% 13.9% - 1,045 1,008 3.7% 1.5% 2.2% 1,284 1,218 5.5% 3.6% 1.9% 4,364 3,623 20.4% 20.4% - 6,406 5,310 20.6% 15.3%	<u></u>	<u> </u>	<u> </u>		
5,218 4,850 7.6% 5.5% 2.1% 117 150 -22.1% -22.1% - 372 319 16.4% 11.6% 4.8% 489 469 4.1% 0.8% 3.3% 1,882 1,704 10.4% 10.4% - 1,111 983 13.0% 7.6% 5.4% 2,994 2,688 11.4% 9.4% 2.0% 210 220 -4.7% -4.7% - 242 254 -5.1% -8.3% 3.2% 452 475 -4.9% -6.6% 1.7% 239 210 13.9% 13.9% - 1,045 1,008 3.7% 1.5% 2.2% 1,284 1,218 5.5% 3.6% 1.9% 4,364 3,623 20.4% 20.4% - 4,364 3,623 20.4% 20.4% - 6,406 5,310 20.6% 15.3%	2,448	2,285	7.2%	7.2%	-
117 150 -22.1% -22.1% - 372 319 16.4% 11.6% 4.8% 489 469 4.1% 0.8% 3.3% 1,882 1,704 10.4% 10.4% - 1,111 983 13.0% 7.6% 5.4% 2,994 2,688 11.4% 9.4% 2.0% 210 220 -4.7% -4.7% - 242 254 -5.1% -8.3% 3.2% 452 475 -4.9% -6.6% 1.7% 239 210 13.9% 13.9% - 1,045 1,008 3.7% 1.5% 2.2% 1,284 1,218 5.5% 3.6% 1.9% 4,364 3,623 20.4% 20.4% - 4,364 3,623 20.4% 20.4% - 4,364 3,623 20.4% 20.4% - 2,302 1,540 49.5% 49.5%	2,770	2,565	8.0%	4.1%	3.9%
372 319 16.4% 11.6% 4.8% 489 469 4.1% 0.8% 3.3% 1,882 1,704 10.4% 10.4% - 1,111 983 13.0% 7.6% 5.4% 2,994 2,688 11.4% 9.4% 2.0% 210 220 -4.7% -4.7% - 242 254 -5.1% -8.3% 3.2% 452 475 -4.9% -6.6% 1.7% 239 210 13.9% 13.9% - 1,045 1,008 3.7% 1.5% 2.2% 1,284 1,218 5.5% 3.6% 1.9% 4,364 3,623 20.4% 20.4% - 6,406 5,310 20.6% 15.3% 5.3% 10,770 8,933 20.6% 15.3% 5.3% 2,076 1,397 48.6% 42.2% 6.4% 4,378 2,937 49.1% 46.0	5,218	4,850	7.6%	5.5%	2.1%
372 319 16.4% 11.6% 4.8% 489 469 4.1% 0.8% 3.3% 1,882 1,704 10.4% 10.4% - 1,111 983 13.0% 7.6% 5.4% 2,994 2,688 11.4% 9.4% 2.0% 210 220 -4.7% -4.7% - 242 254 -5.1% -8.3% 3.2% 452 475 -4.9% -6.6% 1.7% 239 210 13.9% 13.9% - 1,045 1,008 3.7% 1.5% 2.2% 1,284 1,218 5.5% 3.6% 1.9% 4,364 3,623 20.4% 20.4% - 6,406 5,310 20.6% 15.3% 5.3% 10,770 8,933 20.6% 15.3% 5.3% 2,076 1,397 48.6% 42.2% 6.4% 4,378 2,937 49.1% 46.0					
489 469 4.1% 0.8% 3.3% 1,882 1,704 10.4% 10.4% - 1,111 983 13.0% 7.6% 5.4% 2,994 2,688 11.4% 9.4% 2.0% 210 220 -4.7% -4.7% - 242 254 -5.1% -8.3% 3.2% 452 475 -4.9% -6.6% 1.7% 239 210 13.9% 13.9% - 1,045 1,008 3.7% 1.5% 2.2% 1,284 1,218 5.5% 3.6% 1.9% 4,364 3,623 20.4% 20.4% - 6,406 5,310 20.6% 15.3% 5.3% 10,770 8,933 20.6% 15.3% 5.3% 2,076 1,397 48.6% 49.5% - 2,076 1,397 48.6% 42.2% 6.4% 4,378 2,937 49.1% 41.	117	150	-22.1%	-22.1%	-
1,882 1,704 10.4% 10.4% - 1,111 983 13.0% 7.6% 5.4% 2,994 2,688 11.4% 9.4% 2.0% 210 220 -4.7% -4.7% - 242 254 -5.1% -8.3% 3.2% 452 475 -4.9% -6.6% 1.7% 239 210 13.9% 13.9% - 1,045 1,008 3.7% 1.5% 2.2% 1,284 1,218 5.5% 3.6% 1.9% 4,364 3,623 20.4% 20.4% - 6,406 5,310 20.6% 15.3% 5.3% 10,770 8,933 20.6% 17.4% 3.2% 2,302 1,540 49.5% 49.5% - 2,076 1,397 48.6% 42.2% 6.4% 4,378 2,937 49.1% 46.0% 3.1% 578 407 41.8% 4	372	319	16.4%	11.6%	4.8%
1,111 983 13.0% 7.6% 5.4% 2,994 2,688 11.4% 9.4% 2.0% 210 220 -4.7% -4.7% - 242 254 -5.1% -8.3% 3.2% 452 475 -4.9% -6.6% 1.7% 239 210 13.9% 13.9% - 1,045 1,008 3.7% 1.5% 2.2% 1,284 1,218 5.5% 3.6% 1.9% 4,364 3,623 20.4% 20.4% - 6,406 5,310 20.6% 15.3% 5.3% 10,770 8,933 20.6% 17.4% 3.2% 2,302 1,540 49.5% 49.5% - 2,076 1,397 48.6% 42.2% 6.4% 4,378 2,937 49.1% 46.0% 3.1% 578 407 41.8% 41.8% - 329 112 * *	489	469	4.1%	0.8%	3.3%
1,111 983 13.0% 7.6% 5.4% 2,994 2,688 11.4% 9.4% 2.0% 210 220 -4.7% -4.7% - 242 254 -5.1% -8.3% 3.2% 452 475 -4.9% -6.6% 1.7% 239 210 13.9% 13.9% - 1,045 1,008 3.7% 1.5% 2.2% 1,284 1,218 5.5% 3.6% 1.9% 4,364 3,623 20.4% 20.4% - 6,406 5,310 20.6% 15.3% 5.3% 10,770 8,933 20.6% 17.4% 3.2% 2,302 1,540 49.5% 49.5% - 2,076 1,397 48.6% 42.2% 6.4% 4,378 2,937 49.1% 46.0% 3.1% 578 407 41.8% 41.8% - 329 112 * *					
1,111 983 13.0% 7.6% 5.4% 2,994 2,688 11.4% 9.4% 2.0% 210 220 -4.7% -4.7% - 242 254 -5.1% -8.3% 3.2% 452 475 -4.9% -6.6% 1.7% 239 210 13.9% 13.9% - 1,045 1,008 3.7% 1.5% 2.2% 1,284 1,218 5.5% 3.6% 1.9% 4,364 3,623 20.4% 20.4% - 6,406 5,310 20.6% 15.3% 5.3% 10,770 8,933 20.6% 17.4% 3.2% 2,302 1,540 49.5% 49.5% - 2,076 1,397 48.6% 42.2% 6.4% 4,378 2,937 49.1% 46.0% 3.1% 578 407 41.8% 41.8% - 329 112 * *					
2,994 2,688 11.4% 9.4% 2.0% 210 220 -4.7% -4.7% - 242 254 -5.1% -8.3% 3.2% 452 475 -4.9% -6.6% 1.7% 239 210 13.9% 13.9% - 1,045 1,008 3.7% 1.5% 2.2% 1,284 1,218 5.5% 3.6% 1.9% 4,364 3,623 20.4% 20.4% - 6,406 5,310 20.6% 15.3% 5.3% 10,770 8,933 20.6% 17.4% 3.2% 2,302 1,540 49.5% 49.5% - 2,076 1,397 48.6% 42.2% 6.4% 4,378 2,937 49.1% 46.0% 3.1% 578 407 41.8% 41.8% - 329 112 * * * 907 519 74.7% 72.2%	1,882	1,704	10.4%	10.4%	-
210 220 -4.7% -4.7% - 242 254 -5.1% -8.3% 3.2% 452 475 -4.9% -6.6% 1.7% 239 210 13.9% 13.9% - 1,045 1,008 3.7% 1.5% 2.2% 1,284 1,218 5.5% 3.6% 1.9% 4,364 3,623 20.4% 20.4% - 6,406 5,310 20.6% 15.3% 5.3% 10,770 8,933 20.6% 17.4% 3.2% 2,302 1,540 49.5% 49.5% - 2,076 1,397 48.6% 42.2% 6.4% 4,378 2,937 49.1% 46.0% 3.1% 578 407 41.8% 41.8% - 329 112 * * * 907 519 74.7% 72.2% 2.5% 1,311 1,329 -1.3% -1.3%	1,111	983	13.0%	7.6%	5.4%
242 254 -5.1% -8.3% 3.2% 452 475 -4.9% -6.6% 1.7% 239 210 13.9% 13.9% - 1,045 1,008 3.7% 1.5% 2.2% 1,284 1,218 5.5% 3.6% 1.9% 4,364 3,623 20.4% 20.4% - 6,406 5,310 20.6% 15.3% 5.3% 10,770 8,933 20.6% 17.4% 3.2% 2,302 1,540 49.5% 49.5% - 2,076 1,397 48.6% 42.2% 6.4% 4,378 2,937 49.1% 46.0% 3.1% 578 407 41.8% 41.8% - 329 112 * * * 907 519 74.7% 72.2% 2.5% 1,311 1,329 -1.3% -1.3% - 1,996 1,682 18.7% 13.1%	2,994	2,688	11.4%	9.4%	2.0%
242 254 -5.1% -8.3% 3.2% 452 475 -4.9% -6.6% 1.7% 239 210 13.9% 13.9% - 1,045 1,008 3.7% 1.5% 2.2% 1,284 1,218 5.5% 3.6% 1.9% 4,364 3,623 20.4% 20.4% - 6,406 5,310 20.6% 15.3% 5.3% 10,770 8,933 20.6% 17.4% 3.2% 2,302 1,540 49.5% 49.5% - 2,076 1,397 48.6% 42.2% 6.4% 4,378 2,937 49.1% 46.0% 3.1% 578 407 41.8% 41.8% - 329 112 * * * 907 519 74.7% 72.2% 2.5% 1,311 1,329 -1.3% -1.3% - 1,996 1,682 18.7% 13.1%					
452 475 -4.9% -6.6% 1.7% 239 210 13.9% 13.9% - 1,045 1,008 3.7% 1.5% 2.2% 1,284 1,218 5.5% 3.6% 1.9% 4,364 3,623 20.4% 20.4% - 6,406 5,310 20.6% 15.3% 5.3% 10,770 8,933 20.6% 17.4% 3.2% 2,302 1,540 49.5% 49.5% - 2,076 1,397 48.6% 42.2% 6.4% 4,378 2,937 49.1% 46.0% 3.1% 578 407 41.8% 41.8% - 329 112 * * * 907 519 74.7% 72.2% 2.5% 1,311 1,329 -1.3% - - 1,996 1,682 18.7% 13.1% 5.6% 3,307 3,011 9.9% 6.7%					
239 210 13.9% 13.9% - 1,045 1,008 3.7% 1.5% 2.2% 1,284 1,218 5.5% 3.6% 1.9% 4,364 3,623 20.4% 20.4% - 6,406 5,310 20.6% 15.3% 5.3% 10,770 8,933 20.6% 17.4% 3.2% 2,302 1,540 49.5% 49.5% - 2,076 1,397 48.6% 42.2% 6.4% 4,378 2,937 49.1% 46.0% 3.1% 578 407 41.8% 41.8% - 329 112 * * * 907 519 74.7% 72.2% 2.5% 1,311 1,329 -1.3% -1.3% - 1,996 1,682 18.7% 13.1% 5.6% 3,307 3,011 9.9% 6.7% 3.2% 96 284 -66.2% -66.2% <th></th> <th></th> <th>-</th> <th></th> <th></th>			-		
1,045 1,008 3.7% 1.5% 2.2% 1,284 1,218 5.5% 3.6% 1.9% 4,364 3,623 20.4% 20.4% - 6,406 5,310 20.6% 15.3% 5.3% 10,770 8,933 20.6% 17.4% 3.2% 2,302 1,540 49.5% 49.5% - 2,076 1,397 48.6% 42.2% 6.4% 4,378 2,937 49.1% 46.0% 3.1% 578 407 41.8% 41.8% - 329 112 * * * 907 519 74.7% 72.2% 2.5% 1,311 1,329 -1.3% -1.3% - 1,996 1,682 18.7% 13.1% 5.6% 3,307 3,011 9.9% 6.7% 3.2% 96 284 -66.2% -66.2% - 1,653 1,564 5.7% 0.9% </th <th>452</th> <th>475</th> <th>-4.9%</th> <th>-6.6%</th> <th>1.7%</th>	452	475	-4.9%	-6.6%	1.7%
1,045 1,008 3.7% 1.5% 2.2% 1,284 1,218 5.5% 3.6% 1.9% 4,364 3,623 20.4% 20.4% - 6,406 5,310 20.6% 15.3% 5.3% 10,770 8,933 20.6% 17.4% 3.2% 2,302 1,540 49.5% 49.5% - 2,076 1,397 48.6% 42.2% 6.4% 4,378 2,937 49.1% 46.0% 3.1% 578 407 41.8% 41.8% - 329 112 * * * 907 519 74.7% 72.2% 2.5% 1,311 1,329 -1.3% -1.3% - 1,996 1,682 18.7% 13.1% 5.6% 3,307 3,011 9.9% 6.7% 3.2% 96 284 -66.2% -66.2% - 1,653 1,564 5.7% 0.9% </th <th>000</th> <th>040</th> <th>40.00/</th> <th>40.00/</th> <th></th>	000	040	40.00/	40.00/	
1,284 1,218 5.5% 3.6% 1.9% 4,364 3,623 20.4% 20.4% - 6,406 5,310 20.6% 15.3% 5.3% 10,770 8,933 20.6% 17.4% 3.2% 2,302 1,540 49.5% 49.5% - 2,076 1,397 48.6% 42.2% 6.4% 4,378 2,937 49.1% 46.0% 3.1% 578 407 41.8% 41.8% - 329 112 * * * 907 519 74.7% 72.2% 2.5% 1,311 1,329 -1.3% -1.3% - 1,996 1,682 18.7% 13.1% 5.6% 3,307 3,011 9.9% 6.7% 3.2% 96 284 -66.2% -66.2% - 1,653 1,564 5.7% 0.9% 4.8% 1,749 1,848 -5.4% -9.4%					
4,364 3,623 20.4% 20.4% - 6,406 5,310 20.6% 15.3% 5.3% 10,770 8,933 20.6% 17.4% 3.2% 2,302 1,540 49.5% 49.5% - 2,076 1,397 48.6% 42.2% 6.4% 4,378 2,937 49.1% 46.0% 3.1% 578 407 41.8% 41.8% - 329 112 * * * 907 519 74.7% 72.2% 2.5% 1,311 1,329 -1.3% -1.3% - 1,996 1,682 18.7% 13.1% 5.6% 3,307 3,011 9.9% 6.7% 3.2% 96 284 -66.2% -66.2% - 1,653 1,564 5.7% 0.9% 4.8% 1,749 1,848 -5.4% -9.4% 4.0% 76 63 21.0% 21.0% - 76 63 21.0% -36.6% -38.5% <td< th=""><th></th><th>-</th><th>-</th><th></th><th></th></td<>		-	-		
6,406 5,310 20.6% 15.3% 5.3% 10,770 8,933 20.6% 17.4% 3.2% 2,302 1,540 49.5% 49.5% - 2,076 1,397 48.6% 42.2% 6.4% 4,378 2,937 49.1% 46.0% 3.1% 578 407 41.8% 41.8% - 329 112 * * * 907 519 74.7% 72.2% 2.5% 1,311 1,329 -1.3% -1.3% - 1,996 1,682 18.7% 13.1% 5.6% 3,307 3,011 9.9% 6.7% 3.2% 96 284 -66.2% -66.2% - 1,653 1,564 5.7% 0.9% 4.8% 1,749 1,848 -5.4% -9.4% 4.0% 76 63 21.0% 21.0% - 76 63 21.0% -36.6%	1,204	1,210	5.5%	3.0%	1.9%
6,406 5,310 20.6% 15.3% 5.3% 10,770 8,933 20.6% 17.4% 3.2% 2,302 1,540 49.5% 49.5% - 2,076 1,397 48.6% 42.2% 6.4% 4,378 2,937 49.1% 46.0% 3.1% 578 407 41.8% 41.8% - 329 112 * * * 907 519 74.7% 72.2% 2.5% 1,311 1,329 -1.3% -1.3% - 1,996 1,682 18.7% 13.1% 5.6% 3,307 3,011 9.9% 6.7% 3.2% 96 284 -66.2% -66.2% - 1,653 1,564 5.7% 0.9% 4.8% 1,749 1,848 -5.4% -9.4% 4.0% 76 63 21.0% 21.0% - 76 63 21.0% -36.6%	4 364	3 623	20.4%	20.4%	_
10,770 8,933 20.6% 17.4% 3.2% 2,302 1,540 49.5% 49.5% - 2,076 1,397 48.6% 42.2% 6.4% 4,378 2,937 49.1% 46.0% 3.1% 578 407 41.8% 41.8% - 329 112 * * * 907 519 74.7% 72.2% 2.5% 1,311 1,329 -1.3% - - 1,996 1,682 18.7% 13.1% 5.6% 3,307 3,011 9.9% 6.7% 3.2% 96 284 -66.2% -66.2% - 1,653 1,564 5.7% 0.9% 4.8% 1,749 1,848 -5.4% -9.4% 4.0% 76 63 21.0% 21.0% - 352 556 -36.6% -38.5% 1.9%					5.3%
2,302 1,540 49.5% 49.5% - 2,076 1,397 48.6% 42.2% 6.4% 4,378 2,937 49.1% 46.0% 3.1% 578 407 41.8% 41.8% - 329 112 * * * 907 519 74.7% 72.2% 2.5% 1,311 1,329 -1.3% -1.3% - 1,996 1,682 18.7% 13.1% 5.6% 3,307 3,011 9.9% 6.7% 3.2% 96 284 -66.2% -66.2% - 1,653 1,564 5.7% 0.9% 4.8% 1,749 1,848 -5.4% -9.4% 4.0% 76 63 21.0% 21.0% - 76 63 21.0% -36.6% -38.5% 1.9%			•		
2,076 1,397 48.6% 42.2% 6.4% 4,378 2,937 49.1% 46.0% 3.1% 578 407 41.8% 41.8% - 329 112 * * * 907 519 74.7% 72.2% 2.5% 1,311 1,329 -1.3% - - 1,996 1,682 18.7% 13.1% 5.6% 3,307 3,011 9.9% 6.7% 3.2% 96 284 -66.2% -66.2% - 1,653 1,564 5.7% 0.9% 4.8% 1,749 1,848 -5.4% -9.4% 4.0% 76 63 21.0% 21.0% - 352 556 -36.6% -38.5% 1.9%	,	5,555			
4,378 2,937 49.1% 46.0% 3.1% 578 407 41.8% 41.8% - 329 112 * * * 907 519 74.7% 72.2% 2.5% 1,311 1,329 -1.3% -1.3% - 1,996 1,682 18.7% 13.1% 5.6% 3,307 3,011 9.9% 6.7% 3.2% 96 284 -66.2% -66.2% - 1,653 1,564 5.7% 0.9% 4.8% 1,749 1,848 -5.4% -9.4% 4.0% 76 63 21.0% 21.0% - 76 63 21.0% -36.6% -38.5% 1.9%	2,302	1,540	49.5%	49.5%	-
578 407 41.8% 41.8% - 329 112 * * * * 907 519 74.7% 72.2% 2.5% 1,311 1,329 -1.3% - - 1,996 1,682 18.7% 13.1% 5.6% 3,307 3,011 9.9% 6.7% 3.2% 96 284 -66.2% -66.2% - 1,653 1,564 5.7% 0.9% 4.8% 1,749 1,848 -5.4% -9.4% 4.0% 76 63 21.0% 21.0% - 76 63 21.0% 21.0% - 352 556 -36.6% -38.5% 1.9%	2,076	1,397	48.6%	42.2%	6.4%
329 112 * * 907 519 74.7% 72.2% 2.5% 1,311 1,329 -1.3% -1.3% - 1,996 1,682 18.7% 13.1% 5.6% 3,307 3,011 9.9% 6.7% 3.2% 96 284 -66.2% -66.2% - 1,653 1,564 5.7% 0.9% 4.8% 1,749 1,848 -5.4% -9.4% 4.0% 76 63 21.0% 21.0% - 352 556 -36.6% -38.5% 1.9%	4,378	2,937	49.1%	46.0%	3.1%
329 112 * * 907 519 74.7% 72.2% 2.5% 1,311 1,329 -1.3% -1.3% - 1,996 1,682 18.7% 13.1% 5.6% 3,307 3,011 9.9% 6.7% 3.2% 96 284 -66.2% -66.2% - 1,653 1,564 5.7% 0.9% 4.8% 1,749 1,848 -5.4% -9.4% 4.0% 76 63 21.0% 21.0% - 352 556 -36.6% -38.5% 1.9%					
329 112 907 519 74.7% 72.2% 2.5% 1,311 1,329 -1.3% -1.3% - 1,996 1,682 18.7% 13.1% 5.6% 3,307 3,011 9.9% 6.7% 3.2% 96 284 -66.2% -66.2% - 1,653 1,564 5.7% 0.9% 4.8% 1,749 1,848 -5.4% -9.4% 4.0% 76 63 21.0% 21.0% - 76 63 21.0% -38.5% 1.9%	578	407	41.8%	41.8%	-
1,311 1,329 -1.3% -1.3% - 1,996 1,682 18.7% 13.1% 5.6% 3,307 3,011 9.9% 6.7% 3.2% 96 284 -66.2% -66.2% - 1,653 1,564 5.7% 0.9% 4.8% 1,749 1,848 -5.4% -9.4% 4.0% 76 63 21.0% 21.0% - 352 556 -36.6% -38.5% 1.9%	329	112	*	*	*
1,996 1,682 18.7% 13.1% 5.6% 3,307 3,011 9.9% 6.7% 3.2% 96 284 -66.2% -66.2% - 1,653 1,564 5.7% 0.9% 4.8% 1,749 1,848 -5.4% -9.4% 4.0% 76 63 21.0% 21.0% - 352 556 -36.6% -38.5% 1.9%	907	519	74.7%	72.2%	2.5%
1,996 1,682 18.7% 13.1% 5.6% 3,307 3,011 9.9% 6.7% 3.2% 96 284 -66.2% -66.2% - 1,653 1,564 5.7% 0.9% 4.8% 1,749 1,848 -5.4% -9.4% 4.0% 76 63 21.0% 21.0% - 352 556 -36.6% -38.5% 1.9%					
3,307 3,011 9.9% 6.7% 3.2% 96 284 -66.2% -66.2% - 1,653 1,564 5.7% 0.9% 4.8% 1,749 1,848 -5.4% -9.4% 4.0% 76 63 21.0% 21.0% - 352 556 -36.6% -38.5% 1.9%	1,311	1,329	-1.3%	-1.3%	-
96 284 -66.2% -66.2% - 1,653 1,564 5.7% 0.9% 4.8% 1,749 1,848 -5.4% -9.4% 4.0% 76 63 21.0% 21.0% - 352 556 -36.6% -38.5% 1.9%	1,996	1,682	18.7%	13.1%	5.6%
1,653 1,564 5.7% 0.9% 4.8% 1,749 1,848 -5.4% -9.4% 4.0% 76 63 21.0% 21.0% - 352 556 -36.6% -38.5% 1.9%	3,307	3,011	9.9%	6.7%	3.2%
1,653 1,564 5.7% 0.9% 4.8% 1,749 1,848 -5.4% -9.4% 4.0% 76 63 21.0% 21.0% - 352 556 -36.6% -38.5% 1.9%					
1,749 1,848 -5.4% -9.4% 4.0% 76 63 21.0% 21.0% - 352 556 -36.6% -38.5% 1.9%					
76 63 21.0% 21.0% - 352 556 -36.6% -38.5% 1.9%			-		
352 556 -36.6% -38.5% 1.9%	1,749	1,848	-5.4%	-9.4%	4.0%
352 556 -36.6% -38.5% 1.9%			04.007	04.00/	
					1.00/
428 619 -30.7% -32.4% 1.7%			-		
	428	619	-30.7%	-32.4%	1.7%

REPORTED SALES vs. PRIOR PERIOD (\$MM)
THIRD QUARTER

		_	THIND QUARTE	% Change	
	<u>2021</u>	2020	Reported	Operational (1)	Currency
PULMONARY HYPERTENSION					<u></u>
US	610	510	19.7%	19.7%	
Intl	258	239	7.9%	8.4%	-0.5%
WW	868	749	15.9%	16.1%	-0.2%
OPSUMIT	000	143	13.570	10.170	0.270
US	299	244	22.8%	22.8%	_
Intl	159	148	7.4%	7.8%	-0.4%
WW	458	392	17.0%	17.1%	-0.1%
LIDTDAVI					
<u>UPTRAVI</u> US	265	226	17.3%	17.3%	
Intl	44	34	30.4%	28.8%	1.6%
WW	309	260	19.0%	18.8%	0.2%
OTHER PULMONARY HYPERTENSION	309	200	19.076	10.070	0.276
US	47	40	14.4%	14.4%	_
Intl	54	57	-4.4%	-2.1%	-2.3%
WW	101	97	3.4%	4.8%	-1.4%
CARDIOVASCULAR / METABOLISM / OTHER	101	0.	0.470	4.070	1.470
US	800	931	-14.0%	-14.0%	_
Intl	333	351	-5.1%	-8.2%	3.1%
WW	1,133	1,281	-11.5%	-12.4%	0.9%
XARELTO	•				
US	636	630	0.8%	0.8%	-
Intl	<u> </u>	-	-	-	-
WW	636	630	0.8%	0.8%	-
INVOKANA / INVOKAMET					
US	66	156	-57.4%	-57.4%	-
Intl	67	68	-1.0%	-4.3%	3.3%
WW	133	224	-40.3%	-41.3%	1.0%
PROCRIT / EPREX					
US	47	69	-30.9%	-30.9%	-
Intl	65	63	3.1%	0.5%	2.6%
WW	112	132	-14.6%	-15.8%	1.2%
<u>OTHER</u>					
US	51	75	-32.6%	-32.6%	-
Intl	200	219	-8.7%	-11.9%	3.2%
WW	251	294	-14.8%	-17.2%	2.4%
TOTAL PHARMACEUTICAL					
US	7,221	6,438	12.2%	12.2%	-
Intl	5,773	4,980	15.9%	14.6%	1.3%
ww	\$ 12,994	11,418	13.8%	13.2%	0.6%

		NINE MONTHS		
			% Change	
<u>2021</u>	2020	Reported	Operational (1)	Currency
4 770	4 5 4 4	45.40/	45.40/	
1,778	1,541	15.4%	15.4%	-
821	742	10.7%	7.3%	3.4%
2,599	2,283	13.9%	12.7%	1.2%
204	700	40.00/	40.00/	
861	729	18.2%	18.2%	-
510	458	11.3%	7.7%	3.6%
1,371	1,187	15.5%	14.1%	1.4%
792	692	14.6%	14.6%	-
135	100	34.6%	27.9%	6.7%
927	792	17.1%	16.2%	0.9%
125	121	2.8%	2.8%	-
176	183	-3.7%	-5.0%	1.3%
301	304	-1.1%	-1.9%	0.8%
2,379	2,574	-7.6%	-7.6%	-
1,007	1,052	-4.2%	-9.3%	5.1%
3,386	3,625	-6.6%	-8.1%	1.5%
1,794	1,716	4.5%	4.5%	-
	<u>-</u>	-	-	-
1,794	1,716	4.5%	4.5%	-
0.40	405	00.40/	00.40/	
249	405	-38.4%	-38.4%	- 0.40/
194	173	11.9%	5.8%	6.1%
443	578	-23.4%	-25.2%	1.8%
460	245	04.70/	24.70/	_
168 198	215 208	-21.7% -4.7%	-21.7%	- 5.0%
			-9.7%	
366	423	-13.4%	-15.8%	2.4%
168	238	-29.3%	-29.3%	-
615	670	-8.3%	-13.1%	4.8%
783	908	-13.8%	-17.3%	3.5%
20,536	18,619	10.3%	10.3%	-
17,256	14,685	17.5%	12.5%	5.0%
\$ 37,792	33,304	13.5%	11.3%	2.2%
 =			,	

REPORTED SALES vs. PRIOR PERIOD (\$MM)

				THIRD QUARTE	R	
					% Change	
MEDICAL DEVICES SEGMENT (2)	1	<u> 2021</u>	2020	Reported	Operational (1)	<u>Currency</u>
INTERVENTIONAL SOLUTIONS						
US	\$	444	399	11.1%	11.1%	-
Intl		513	437	17.7%	15.1%	2.6%
WW	,	957	836	14.5%	13.2%	1.3%
<u>ORTHOPAEDICS</u>						
US		1,249	1,308	-4.5%	-4.5%	-
Intl		843	774	8.8%	6.8%	2.0%
WW		2,093	2,083	0.5%	-0.3%	0.8%
<u>HIPS</u>						
US		210	221	-5.3%	-5.3%	-
Intl		146	124	18.8%	16.0%	2.8%
WW		356	345	3.3%	2.3%	1.0%
KNEES						
US		184	205	-9.8%	-9.8%	-
Intl		131	102	28.1%	25.9%	2.2%
WW		316	308	2.8%	2.1%	0.7%
<u>TRAUMA</u>						
US		455	433	5.3%	5.3%	-
Intl		260	253	2.4%	0.9%	1.5%
WW		715	685	4.2%	3.7%	0.5%
SPINE, SPORTS & OTHER						
US		400	449	-11.1%	-11.1%	-
Intl		306	295	3.5%	1.5%	2.0%
WW		705	745	-5.3%	-6.1%	0.8%

		N	IINE MONTHS		
				% Change	
	<u>2021</u>	2020	Reported	Operational (1)	Currency
	1,353	1,019	32.7%	32.7%	-
	1,599	1,134	41.1%	34.3%	6.8%
	2,952	2,153	37.1%	33.6%	3.5%
	3,821	3,427	11.5%	11.5%	_
	2,611	2,145	21.7%	15.4%	6.3%
_	6,433	5,572	15.4%	13.0%	2.4%
	0,433	5,572	15.4%	13.0%	2.470
	654	564	15.9%	15.9%	_
	451	344	31.3%	24.1%	7.2%
_	1,105	908	21.8%	19.0%	2.8%
	1,103	300	21.076	19.076	2.076
	579	527	10.0%	10.0%	_
	403	298	35.4%	28.2%	7.2%
_	983	825	19.2%	16.6%	2.6%
	303	023	19.276	10.076	2.078
	1,352	1,194	13.3%	13.3%	_
	805	698	15.2%	9.5%	5.7%
_	2,157	1,892	14.0%	11.9%	2.1%
	2,137	1,032	14.076	11.976	2.176
	1,236	1,142	8.2%	8.2%	_
	952	805	18.2%	12.0%	6.2%
_	2,187	1,947	12.3%	9.7%	2.6%
	2,107	1,547	12.576	3.770	2.076

REPORTED SALES vs. PRIOR PERIOD (\$MM)

	THIRD QUARTER				
			% Change		
	2021	2020	Reported	Operational (1)	Currency
SURGERY					
US	948	913	3.9%	3.9%	-
Intl	1,457	1,239	17.6%	14.8%	2.8%
WW	2,405	2,152	11.8%	10.2%	1.6%
ADVANCED					
US	440	421	4.6%	4.6%	-
Intl	705	579	21.8%	18.4%	3.4%
WW	1,144	1,000	14.6%	12.6%	2.0%
<u>GENERAL</u>					
US	508	492	3.3%	3.3%	-
Intl	752	660	13.9%	11.7%	2.2%
WW	1,261	1,152	9.4%	8.1%	1.3%
VISION					
US	475	473	0.6%	0.6%	-
Intl	714	608	17.4%	17.4%	0.0%
WW	1,189	1,081	10.1%	10.0%	0.1%
CONTACT LENSES / OTHER					
US	359	375	-4.3%	-4.3%	-
Intl	522	455	14.9%	15.2%	-0.3%
WW	882	830	6.2%	6.4%	-0.2%
<u>SURGICAL</u>					
US	117	98	19.6%	19.6%	-
Intl	191	153	24.7%	23.7%	1.0%
WW	308	251	22.7%	22.1%	0.6%
TOTAL MEDICAL DEVICES					
US	3,117	3,092	0.8%	0.8%	-
Inti	3,527	3,058	15.4%	13.3%	2.1%
WW	\$ 6,644	6,150	8.0%	7.0%	1.0%

Note: Columns and rows within tables may not add due to rounding. Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely.

NINE MONTHS								
		% Change						
<u>2021</u>	2020	Reported	Operational (1)	Currency				
2,881	2,247	28.2%	28.2%	-				
4,418	3,556	24.2%	18.4%	5.8%				
7,299	5,803	25.8%	22.2%	3.6%				
1,304	1,079	20.9%	20.9%	-				
2,126	1,644	29.3%	23.1%	6.2%				
3,430	2,723	26.0%	22.2%	3.8%				
1,577	1,168	35.0%	35.0%	-				
2,292	1,912	19.9%	14.5%	5.4%				
3,869	3,080	25.6%	22.3%	3.3%				
1,414	1,160	21.9%	21.9%	-				
2,103	1,683	25.0%	22.0%	3.0%				
3,517	2,843	23.7%	22.0%	1.7%				
		.=	4= 00/					
1,082	924	17.0%	17.0%	-				
1,525	1,274	19.8%	17.3%	2.5%				
2,607	2,198	18.6%	17.2%	1.4%				
		44.407	44.407					
333	236	41.1%	41.1%	-				
577	409	41.1%	36.7%	4.4%				
910	645	41.1%	38.3%	2.8%				
9,470	7 050	20.6%	20.6%					
•	7,852 9.549	26.0%	20.5%	- 5.5%				
10,731 \$ 20,201	8,518 16,270		20.5% 20.5%					
\$ 20,201	16,370	23.4%	20.5%	2.9%				

^{*} Percentage greater than 100% or not meaningful

⁽¹⁾ Operational growth excludes the effect of translational currency

⁽²⁾ Unaudited

⁽³⁾ Certain prior year amounts have been reclassified to conform to current year product disclosures

⁽⁴⁾ Reported as U.S. sales